Coptis Chinensis affects the function of glioma cells through the down-regulation of phosphorylation of STAT3 by reducing HDAC3

Li, Jiangan; Ni, Lulu; Li, Bing; Wang, Mingdeng; Ding, Zhengnian; Xiong, Chao; Lu, Xiao‐Jie

doi:10.1186/s12906-017-2029-0

Cited by 13 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…C. Rhizoma extract induces glioma cell apoptosis. Under treatment with C. Rhizoma extract, the expression of proteins associated with apoptosis was altered and involved the reduction of total Caspase-3 and induced cleavage Caspase-3 ( Li J. et al, 2017 ). The water extracts of C. Rhizoma exerted apoptotic effects in immortalized human oral keratinocytes through the mitochondrial signaling pathway, represented by mitochondrial cytochrome-C release and Caspase-3 activation ( Lee et al, 2006 ).…”

Section: Antitumor Effects and Corresponding Mechanismsmentioning

confidence: 99%

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Chen

Liang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer is a serious disease with an increasing number of reported cases and high mortality worldwide. Gastrointestinal cancer defines a group of cancers in the digestive system, e.g., liver cancer, colorectal cancer, and gastric cancer. Coptidis Rhizoma (C. Rhizoma; Huanglian, in Chinese) is a classical Chinese medicinal botanical drug for the treatment of gastrointestinal disorders and has been shown to have a wide variety of pharmacological activity, including antifungal, antivirus, anticancer, antidiabetic, hypoglycemic, and cardioprotective effects. Recent studies on C. Rhizoma present significant progress on its anticancer effects and the corresponding mechanisms as well as its clinical applications. Herein, keywords related to C. Rhizoma, cancer, gastrointestinal cancer, and omics were searched in PubMed and the Web of Science databases, and more than three hundred recent publications were reviewed and discussed. C. Rhizoma extract along with its main components, berberine, palmatine, coptisine, magnoflorine, jatrorrhizine, epiberberine, oxyepiberberine, oxyberberine, dihydroberberine, columbamine, limonin, and derivatives, are reviewed. We describe novel and classic anticancer mechanisms from various perspectives of pharmacology, pharmaceutical chemistry, and pharmaceutics. Researchers have transformed the chemical structures and drug delivery systems of these components to obtain better efficacy and bioavailability of C. Rhizoma. Furthermore, C. Rhizoma in combination with other drugs and their clinical application are also summarized. Taken together, C. Rhizoma has broad prospects as a potential adjuvant candidate against cancers, making it reasonable to conduct additional preclinical studies and clinical trials in gastrointestinal cancer in the future.

show abstract

Section: Antitumor Effects and Corresponding Mechanismsmentioning

confidence: 99%

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Chen

Liang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Many studies have shown that Coptis Rhizoma and its extract have obvious anti-glioma effects. In vivo and in vitro experiments have shown that coptis chinensis granules inhibited the proliferation of glioma cells, arrested cell cycle in G2/M phase and induced apoptosis via the down-regulation of photosynthesis of STAT3 by reducing HDAC3 (68). Berberine (Figure 2M) not only significantly inhibited inflammatory cytokine Caspase-1 activation via ERK1/2 signaling and subsequently decreased production of IL-1β and IL-18 in U251 and U87 cells, but inhibited the process of EMT through upregulating the protein expression of β-catenin, α-catenin, and downregulating the protein expression of vimentin, α-SMA, so, it could effectively inhibit glioma cell proliferation, invasion and metastasis (69).…”

Section: Coptis Rhizomamentioning

confidence: 99%

A review of traditional Chinese medicine for treatment of glioblastoma

Wang

et al. 2019

BST

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common primary malignant intracranial tumor. Due to its high morbidity, high mortality, high recurrence rate, and low cure rate, it has brought great difficulty for treatment. Although the current treatment is multimodal, including surgical resection, radiotherapy, and chemotherapy, it does not significantly improve survival time. The dismal prognosis and inevitable recurrence as well as resistance to chemoradiotherapy may be related to its highly cellular heterogeneity and multiple subclonal populations. Traditional Chinese medicine has its own unique advantages in the prevention and treatment of it. A comprehensive literature search of anti-glioblastoma active ingredients and derivatives from traditional Chinese medicine was carried out in literature published in PubMed, Scopus, Web of Science Cochrane library, CNKI, Wanfang, and VIP database. Hence, this article systematically reviews experimental research progress of some traditional Chinese medicine in treatment of glioblastoma from two aspects: strengthening vital qi and eliminating pathogenic qi. Among, strengthening vital qi medicine includes panax ginseng, licorice, lycium barbarum, angelica sinensis; eliminating pathogenic medicine includes salvia miltiorrhiza bunge, scutellaria baicalensis, coptis rhizoma, thunder god vine, and sophora flavescens. We found that the same active ingredient can act on different signaling pathways, such as ginsenoside Rg3 inhibited proliferation and induced apoptosis via the AKT, MEK signal pathway. Hence, this multi-target, multi-level pathway may bring on a new dawn for the treatment of glioblastoma.

show abstract

“…In addition, efforts have been made to examine the potential therapeutic and biological functions of CC, not as a single compound, but as multi-compounds, for cancer treatment. CC has been shown to exert an anticancer effect through the downregulation of signal transducer and activator of transcription (STAT)2 phosphorylation by reducing the level of histone deacetylase 2 (HDAC2) in glioma cells and inhibiting hepatocellular carcinoma cell growth through non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1) activation (14,15). In non-small cell lung cancer (NSCLC) cells, CC has been shown to inhibit growth and metastasis, and to induce cell apoptosis (16).…”

Section: Cancer Cell-specific Anticancer Effects Of Coptis Chinensis On Gefitinib-resistant Lung Cancer Cells Are Mediated Through the Sumentioning

confidence: 99%

Cancer cell‑specific anticancer effects of Coptis�chinensis on gefitinib‑resistant lung cancer cells are mediated through the suppression of Mcl‑1 and Bcl‑2

Kim

et al. 2020

Int J Oncol

View full text Add to dashboard Cite

The epider mal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), gefitinib, is an effective therapeutic drug used in the treatment of non-small cell lung cancers (NSCLCs) harboring EGFR mutations. However, acquired resistance significantly limits the efficacy of EGFR-TKIs and consequently, the current chemotherapeutic strategies for NSCLCs. It is, therefore, necessary to overcome this resistance. In the present study, the anticancer potential of natural extracts of Coptis chinensis (ECC) against gefitinib-resistant (GR) NSCLC cells were investigated in vitro and in vivo. ECC inhibited the viability, migration and invasion, and effectively induced the apoptosis of GR cells. These effects were associated with the suppression of EGFR/AKT signaling and the expression of anti-apoptotic proteins, Mcl-1 and Bcl-2, which were overexpressed in GR NSCLC cells. Combination treatment with ECC and gefitinib enhanced the sensitivity of GR cells to gefitinib in vitro, but not in vivo. However, ECC increased the survival of individual zebrafish without affecting the anticancer effect to cancer cells in vivo, which indicated a specific cytotoxic effect of ECC on cancer cells, but not on normal cells; this is an important property for the development of novel anticancer drugs. On the whole, the findings of the present study indicate the potential of ECC for use in the treatment of NSCLC, particularly in combination with EGFR-TKI therapy, in EGFR-TKI-resistant cancers.

show abstract

Coptis Chinensis affects the function of glioma cells through the down-regulation of phosphorylation of STAT3 by reducing HDAC3

Cited by 13 publications

References 28 publications

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

A review of traditional Chinese medicine for treatment of glioblastoma

Cancer cell‑specific anticancer effects of Coptis�chinensis on gefitinib‑resistant lung cancer cells are mediated through the suppression of Mcl‑1 and Bcl‑2

Contact Info

Product

Resources

About